First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Clinical trial NCT05586061 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05586061
- Sponsor
- Qilu Hospital of Shandong University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-10
- Primary completion
- 2024-12-29
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.